Blood dendritic cells in patients with chronic lymphocytic leukaemia

Area of Science:

• Immunology
• Hematology
• Cancer Research

Background:

• Dendritic cells (DCs), including myeloid (MDC) and plasmacytoid (PDC) subsets, are crucial for initiating immune responses.
• Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of malignant B cells, often associated with immune dysregulation.

Purpose of the Study:

• To investigate the status of MDC and PDC subsets in patients with newly diagnosed CLL.
• To explore the potential of generating functional monocyte-derived DCs (moDCs) from CLL patients for immunotherapeutic applications.

Main Methods:

• Quantification of MDC and PDC subsets in CLL patients and healthy controls.
• Analysis of chemokine secretion (CCL22, CXCL12) by leukaemic cells.
• Differentiation of CD14+ monocytes from CLL patients into moDCs.
• Assessment of moDC function, including IL-12p70 secretion and chemokine-driven migration.

Main Results:

• A significant reduction in both MDC and PDC subsets was observed in CLL patients at diagnosis compared to controls.
• Leukaemic cells from CLL patients exhibited high secretion of CCL22 and CXCL12, potentially contributing to DC subset reduction.
• Monocytes from CLL patients could be differentiated into functional moDCs secreting IL-12p70.
• These CLL-derived moDCs demonstrated efficient migration in response to CCL19/MIP-3beta.

Conclusions:

• CLL is associated with a deficiency in myeloid and plasmacytoid dendritic cells, likely due to chemokines secreted by leukaemic cells.
• Functional, autologous monocyte-derived dendritic cells can be generated from CLL patients.
• These findings suggest a potential strategy for generating functional DCs to overcome DC defects in CLL for immunotherapeutic purposes.